| Literature DB >> 32836530 |
Nicola Di Girolamo1,2, Reint Meursinge Reynders3,4.
Abstract
The COVID-19 pandemic has been characterized by an unprecedented amount of published scientific articles. The aim of this study is to assess the type of articles published during the first 3 months of the COVID-19 pandemic and to compare them with articles published during 2009 H1N1 swine influenza pandemic. Two operators independently extracted and assessed all articles on COVID-19 and on H1N1 swine influenza that had an abstract and were indexed in PubMed during the first 3 months of these pandemics. Of the 2482 articles retrieved on COVID-19, 1165 were included. Over half of them were secondary articles (590, 50.6%). Common primary articles were: human medical research (340, 59.1%), in silico studies (182, 31.7%) and in vitro studies (26, 4.5%). Of the human medical research, the vast majority were observational studies and cases series, followed by single case reports and one randomized controlled trial. Secondary articles were mainly reviews, viewpoints and editorials (373, 63.2%). Limitations were reported in 42 out of 1165 abstracts (3.6%), with 10 abstracts reporting actual methodological limitations. In a similar timeframe, there were 223 articles published on the H1N1 pandemic in 2009. During the COVID-19 pandemic there was a higher prevalence of reviews and guidance articles and a lower prevalence of in vitro and animal research studies compared with the H1N1 pandemic. In conclusions, compared to the H1N1 pandemic, the majority of early publications on COVID-19 does not provide new information, possibly diluting the original data published on this disease and consequently slowing down the development of a valid knowledge base on this disease. Also, only a negligible number of published articles reports limitations in the abstracts, hindering a rapid interpretation of their shortcomings. Researchers, peer reviewers, and editors should take action to flatten the curve of secondary articles. © Akadémiai Kiadó, Budapest, Hungary 2020.Entities:
Keywords: Coronavirus; Covid-19; Healthcare policy; Research quality; SARS-nCoV-2; Study design
Year: 2020 PMID: 32836530 PMCID: PMC7380499 DOI: 10.1007/s11192-020-03632-0
Source DB: PubMed Journal: Scientometrics ISSN: 0138-9130 Impact factor: 3.238
Criteria employed to classify the included articles
| Article type | Study design | Description |
|---|---|---|
| Primary articles | Human medical research | Human medical research refers to articles reporting information on 1 or more human patient/s. In order to be classified as human medical research, an article would need to report individual patient data. Articles in this category were further subcategorized in ‘randomized controlled trials (RCTs)’, ‘observational studies and case series’, and ‘case reports’, based on the following key: articles including a single case were categorized ‘case reports’; articles including 2 or more cases where no randomization were performed were categorized ‘observational studies and case series’; articles including 2 or more cases where randomization of a treatment was performed were categorized ‘RCTs’. We extracted the total number of patients included in human medical research studies |
| In silico research | Primary articles were classified as ‘in silico research’ if they reported the results of any type of computer-based research. Articles in this category were further subcategorized in ‘epidemiological modelling’, ‘biology/biochemistry/bioinformatics studies’, and ‘social media studies’, based on the following key: articles focusing on exploiting platforms or other online tools, such as Google trend in order to extrapolate information or generate any sort of prediction were categorized ‘social media studies’; articles using published or original data to calculate the spreading or impact of COVID-19, including but not limited to epidemiological models and calculations, were classified as ‘epidemiological modelling’; articles using published or original data in order to generate original information solely using computer processing in the field of biology, biochemistry and bioinformatics were classified as ‘biology/biochemistry/bioinformatics studies’. If any part of the work performed by researchers was done without the computer the studies would have been included in the categories in vitro, human medical research or animal research | |
| In vitro research | Primary articles were classified as ‘in vitro research’ if they reported the results of any type of laboratory-based or in vitro research without inclusion of human or animal subjects. Articles in this category were further subcategorized in ‘development/performance of diagnostic technology’, ‘virus-host interaction’, ‘genomic studies’, ‘pharmacological activity in vitro’, ‘viral isolation/transport/elimination’ based on their primary objective and results | |
| Animal research | Research including animal subject/s refers to original clinical research on 1 or more animal subject/s. This category was not further subdivided and individual results of the included studies were reported | |
| Human non-medical research | Primary articles were classified as ‘human non-medical research’ if they reported the result of surveys or studies performed on healthcare professionals. Articles classified as a ‘survey’ were subdivided in ‘surveys to health professionals’ and ‘surveys to the general public’ depending on the population surveyed | |
| Secondary articles | Systematic review | Secondary articles were classified as ‘systematic review’ if they reported the results of a systematic search, whether a narrative review or a meta-analysis was present |
| Review/viewpoint/editorial/letter/news | Secondary articles were classified as ‘review/viewpoint/editorial/letter/news’ if they reported a narrative or graphical representation of previously performed research or previously published information. Since we found it difficult to unequivocally distinguish between articles in this category, the articles were not further subdivided | |
| Guideline/guidance/recommendation | Secondary articles were classified as ‘guideline/guidance/recommendation’ if they reported guidelines or recommendations either on the basis of personal experience, a review of the literature, or a combination of them. This category was further classified in ‘indications for specific department/disease/procedure’ if they reported clinical recommendations for a subset of health professionals and ‘indications for lay public’ if they reported recommendations/indications for the general public | |
| Correspondence to previous research | Secondary articles were classified as ‘correspondence to previous research’ if they reported any type of direct commentary to a recently published article | |
| Erratum/correction | Secondary articles were classified as ‘erratum/correction’ if they reported a mistake with or without a correction for a previously published article |
Fig. 1Modified PRISMA flow diagram showing the article inclusion process
Number of published articles per country, per country population, per country GDP and per country cases
| Number of articles published | Population (thousands, 2018) | Number of published articles per million persons | GDP (2019) | Number of published articles per GDP | Cases declared (March 2nd 2020) | Number of published articles per 100 cases | |
|---|---|---|---|---|---|---|---|
| China | 588 | 1,392,730.00 | 0.422 | 6.1 | 96.39 | 80,134.00 | 0.73 |
| United States | 168 | 326,687.50 | 0.514 | 2.3 | 73.04 | 89.00 | 188.76 |
| Italy | 77 | 60,421.76 | 1.274 | 0.3 | 256.67 | 1,689.00 | 4.56 |
| United Kingdom | 38 | 66,460.34 | 0.572 | 1.4 | 27.14 | 36.00 | 105.56 |
| Japan | 26 | 126,529.10 | 0.205 | 0.7 | 37.14 | 254.00 | 10.24 |
| Singapore | 25 | 5,638.68 | 4.434 | 0.7 | 35.71 | 106.00 | 23.58 |
| Korea, Rep. | 24 | 51,606.63 | 0.465 | 2 | 12 | 4,335.00b | 0.55 |
| India | 21 | 1,352,617.33 | 0.016 | 4.2 | 5 | 3.00 | 700 |
| Germany | 18 | 82,905.78 | 0.217 | 0.6 | 30 | 129.00 | 13.95 |
| France | 18 | 66,977.11 | 0.269 | 1.3 | 13.85 | 130.00 | 13.85 |
| Taiwan | 16 | 23,588.93a | 0.678 | 2.7 | 5.93 | 40.00 | 40 |
| World | 1165 | 7,592,886.80 | 0.153 | 2.9 | 401.72 | 88,416.00 | 1.32 |
Country population for the year 2018 was extracted from The World Bank website. Country GDP for the year 2019 was extracted from the dataset World Economic Outlook. Number of declared cases on March 2nd 2020 (1 month prior our data extraction) was extracted from the data published by the European Centre for Disease Prevention and Control (ECDC)
aUnavailable from The World Bank Data. Retrieved from Taiwan Government statistics website
bUnavailable from the European Centre for Disease Prevention and Control. Retrieved from Worldometer
Results of multivariable logistic regression analysis to determine factors associated with primary article publication in 1165 articles published in the early stages of COVID-19 pandemic
| Primary | Secondary | AOR | 95% CI | |||
|---|---|---|---|---|---|---|
| Days since Jan 1st 2020 | 76 ± 27 days | 80 ± 22 days | 1.012 | 1.004 | 1.020 | 0.004 |
| English | 513 (51.3%) | 487 (48.7%) | 3.02 | 1.99 | 4.58 | < 0.001 |
| Other than English | 62 (37.6%) | 103 (62.4%) | Reference | |||
| None | 5 (16.7%) | 25 (83.3%) | 15.44 | 5.16 | 46.17 | < 0.001 |
| 1-2 | 39 (18.3%) | 174 (81.7%) | 13.12 | 8.02 | 21.46 | < 0.001 |
| 3-5 | 119 (36.8%) | 204 (63.2%) | 5.08 | 3.45 | 7.50 | < 0.001 |
| 6-10 | 228 (65.0% | 123 (35.0% | 1.58 | 1.08 | 2.32 | 0.018 |
| >11 | 184 (74.2%) | 64 (25.8%) | Reference | |||
| China | 356 (60.5%) | 232 (39.5%) | Reference | |||
| United States | 59 (35.1%) | 109 (64.9% | 2.05 | 1.34 | 3.14 | 0.001 |
| Italy | 20 (26.0%) | 57 (74.0%) | 5.68 | 3.16 | 10.19 | < 0.001 |
| United Kingdom | 15 (39.5%) | 23 (60.5% | 1.77 | 0.82 | 3.80 | 0.145 |
| Japan | 22 (84.6%) | 4 (15.4% | 0.223 | 0.069 | 0.724 | 0.013 |
| Singapore | 9 (36.0%) | 16 (64.0%) | 4.17 | 1.70 | 10.27 | 0.02 |
| Korea | 17 (70.8%) | 7 (29.2%) | 0.402 | 0.142 | 1.138 | 0.09 |
| India | 4 (19.0%) | 17 (81.0%) | 7.17 | 2.23 | 23.04 | 0.001 |
| Germany | 5 (27.8%) | 13 (72.2%) | 3.73 | 1.17 | 11.88 | 0.001 |
| France | 8 (44.4%) | 10 (55.6%) | 2.12 | 0.73 | 6.16 | 0.17 |
| Taiwan | 6 (37.5% | 10 (62.5%) | 3.01 | 1.01 | 9.03 | 0.049 |
| Others | 54 (37.0% | 92 (63.0%) | 1.97 | 1.27 | 2.05 | 0.002 |
Continuous data are reported as Median ± IQR. Binary data are reported as number of observed events (percentage over the total). Hosmer–Lemeshow test: Chi square = 12.2; P = 0.14. Nagelkerke R squared: 0.33. aOR adjusted odds ratios, CI Confidence intervals
Fig. 2Bar plot showing the percentage of primary articles (white boxes) and secondary articles (grey boxes) from the 20 journals that published more articles on COVID-19 in the first 3 months of the pandemic. Each bar represents all the articles published by each journal, with the number of articles showed in each box. The bar labelled as “Others” includes all remaining journals that had less than 10 publications each
Type of studies published in the early stages of COVID-19 pandemic and of 2009 H1N1 pandemic
| COVID-19 pandemic | H1N1 2009 pandemic | OR | 95% CI | |||
|---|---|---|---|---|---|---|
| Human medical research | 340 (29.2%) | 71 (31.8%) | Reference | |||
| Single case reports | 58 (17.1%) | 2 (2.8%) | ||||
| Observational studies | 281 (82.6%) | 66 (93.0%) | ||||
| Randomized controlled trials | 1 (0.3%) | 3 (4.2%) | ||||
| Human non-medical research | 20 (1.7%) | 9 (4.0%) | 0.46 | 0.20 | 1.06 | 0.07 |
| In silico | 182 (15.6%) | 30 (13.5%) | 1.27 | 0.80 | 2.01 | 0.32 |
| In vitro | 26 (2.2%) | 33 (14.8%) | 0.16 | 0.09 | 0.29 | < 0.001 |
| Animal research | 7 (0.6%) | 36 (16.1%) | 0.04 | 0.02 | 0.09 | < 0.001 |
| Guidelines/guidance | 193 (16.6%) | 5 (2.2%) | 8.06 | 3.20 | 20.30 | < 0.001 |
| Review/viewpoint/editorial/letter/news | 373 (32.0%) | 38 (17.0%) | 2.05 | 1.35 | 3.12 | 0.001 |
| Systematic review | 23 (2.0%) | 1 (0.4%) | 4.80 | 0.64 | 36.15 | 0.13 |
| Protocol | 1 (0.1%) | 0 (0%) | NA | NA | NA | NA |
Results of univariable logistic regression analysis are reported. Binary data are reported as number of observed events (percentage over the total articles for each pandemic event; for human medical research subcategories, the percentage is calculated over the number of human medical researches). OR odds ratios, CI Confidence intervals
Fig. 3Relationship between days from the start of the pandemics, number of articles published and type of articles during COVID-19 pandemic (red circles) and 2009 H1N1 swine flu pandemic (green circles). On the x axis the days from the start of COVID-19 pandemic (top axis) and the days from the first publication for each pandemic (bottom axis) are reported. On the y axis the total number of articles published for each pandemic is reported. Circle size has been arbitrarily classified in order to show different levels of clinical evidence: at increasing circle size, increase the value of the article (circle size: 1: secondary articles and human non-medical research; 7: in silico research; 8: in vitro research; 9: animal research; 11: case reports; 14: observational studies and case series; 17: randomized controlled trials; 20: systematic reviews). The values were jittered over the y axis to reduce superimposition of data